ArticleBioinformatics (Oxford, England)2020
Network-based prediction of drug-target interactions using an arbitrary-order proximity embedded deep forest.
Article in Bioinformatics (Oxford, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed.
- IIC-DTI: A Contrastive Learning Enhanced Inter-Intra Molecular Fusing Framework for Drug-Target Interaction Prediction.Interdisciplinary sciences, computational life sciences · 2026Article
- Computational framework to quantify synergistic ligand activity in insulin secretion and resistance pathways in type 2 diabetes.Journal of computer-aided molecular design · 2026Article
- AI-driven drug-target interaction prediction: current progress, challenges, and future roadmap for precision medicine.Journal of computer-aided molecular design · 2026Review
- Deep learning-based radiolabelled compound-protein interaction prediction for NDUFS1-targeting radiopharmaceutical discovery.EJNMMI research · 2025Article
- Network-based multi-omics integrative analysis methods in drug discovery: a systematic review.BioData mining · 2025Review
- MCF-DTI: Multi-Scale Convolutional Local-Global Feature Fusion for Drug-Target Interaction Prediction.Molecules (Basel, Switzerland) · 2025Article
- Drug Repurposing: Insights into Current Advances and Future Applications.Current medicinal chemistry · 2025Review
- Article
- Network-based drug repurposing identifies small molecule drugs as immune checkpoint inhibitors for endometrial cancer.Molecular diversity · 2024Article
- Transformer-based models for chemical SMILES representation: A comprehensive literature review.Heliyon · 2024Review
- A review of deep learning methods for ligand based drug virtual screening.Fundamental research · 2024Review
- Drug repurposing based on the DTD-GNN graph neural network: revealing the relationships among drugs, targets and diseases.BMC genomics · 2024Article
- An end-to-end method for predicting compound-protein interactions based on simplified homogeneous graph convolutional network and pre-trained language model.Journal of cheminformatics · 2024Article
- Advancing drug-target interaction prediction: a comprehensive graph-based approach integrating knowledge graph embedding and ProtBert pretraining.BMC bioinformatics · 2023Article
- Prediction of miRNA-Disease Associations by Cascade Forest Model Based on Stacked Autoencoder.Molecules (Basel, Switzerland) · 2023Article
- Drug-target interaction prediction based on protein features, using wrapper feature selection.Scientific reports · 2023Article
- Article
- LM-DTI: a tool of predicting drug-target interactions using the node2vec and network path score methods.Frontiers in genetics · 2023Article
- AlphaFold, Artificial Intelligence (AI), and Allostery.The journal of physical chemistry. B · 2022Review
- iPiDA-LTR: Identifying piwi-interacting RNA-disease associations based on Learning to Rank.PLoS computational biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
motivationSystematic identification of molecular targets among known drugs plays an essential role in drug repurposing and understanding of their unexpected side effects. Computational approaches for prediction of drug-target interactions (DTIs) are highly desired in comparison to traditional experimental assays. Furthermore, recent advances of multiomics technologies and systems biology approaches have generated large-scale heterogeneous, biological networks, which offer unexpected opportunities for network-based identification of new molecular targets among known drugs.
resultsIn this study, we present a network-based computational framework, termed AOPEDF, an arbitrary-order proximity embedded deep forest approach, for prediction of DTIs. AOPEDF learns a low-dimensional vector representation of features that preserve arbitrary-order proximity from a highly integrated, heterogeneous biological network connecting drugs, targets (proteins) and diseases. In total, we construct a heterogeneous network by uniquely integrating 15 networks covering chemical, genomic, phenotypic and network profiles among drugs, proteins/targets and diseases. Then, we build a cascade deep forest classifier to infer new DTIs. Via systematic performance evaluation, AOPEDF achieves high accuracy in identifying molecular targets among known drugs on two external validation sets collected from DrugCentral [area under the receiver operating characteristic curve (AUROC) = 0.868] and ChEMBL (AUROC = 0.768) databases, outperforming several state-of-the-art methods. In a case study, we showcase that multiple molecular targets predicted by AOPEDF are associated with mechanism-of-action of substance abuse disorder for several marketed drugs (such as aripiprazole, risperidone and haloperidol). AVAILABILITY AND IMPLEMENTATION: Source code and data can be downloaded from https://github.com/ChengF-Lab/AOPEDF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.